Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Open-Label, Randomised Study to Assess the Safety and Efficacy of D-0316 Versus Icotinib as First Line Treatment in Patients With EGFR Sensitising Mutation, Locally Advanced or Metastatic NSCLC

NCT04206072 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04206072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04206072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Open-Label, Randomised Study to Assess the Safety and Efficacy of D-0316 Versus Icotinib as First Line Treatment in Patients With EGFR Sensitising Mutation, Locally Advanced or Metastatic NSCLC
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
December 24, 2019
Completion date
July 15, 2025
Enrollment
362 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, non-small cell lung cancer